Scienture

The company aims to improve patient adherence beyond traditional therapies.

Scienture, LLC is a New York-based pharmaceutical company with a pipeline spanning therapeutic areas, indications, and market segments. Its capabilities include R&D, manufacturing, sales, marketing, and commercial operations.

The company responds to general inquiries within three business days.

Scienture reports second-quarter 2026 results, with revenue rising approximately 510% sequentially from Q1 to $343,639, gross margin at about 97.7%, and operating loss improving 48% year over year. It also begins the commercial launch of REZENOPY, its second commercial product.

Aug 2026 · Taiwan NewsNews article

Scienture completes manufacturing of commercial launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg and prepares to begin July shipments to U.S. pharmaceutical wholesalers. Commercial availability is expected in August, while payer access could reach more than 100 million covered lives.

Jul 2026 · NasdaqNews article

Scienture secures formulary coverage for REZENOPY (naloxone HCl) Nasal Spray 10 mg with a large national health plan, expanding potential coverage. The plan covers more than 100 million lives ahead of Scienture’s planned mid-July 2026 U.S. commercial launch. Scienture also adds three sales representatives to its commercial team.

Jun 2026 · StockTitanNews article

Scienture announces that the U.S. Patent and Trademark Office grants U.S. Patent No. 12,622,903 B2 covering REZENOPY (naloxone HCl) Nasal Spray 10 mg. The patent is effective May 12, 2026, and expires February 5, 2041, extending intellectual property protection ahead of the company’s planned mid-July 2026 U.S. launch.

Jun 2026 · StockTitanNews article